{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:20:43Z","timestamp":1791231643451,"version":"4.1.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Capital Funds for Health Improvement and Research","award":["2022-2-8013 (ZXL)"],"award-info":[{"award-number":["2022-2-8013 (ZXL)"]}]},{"DOI":"10.13039\/501100012166","name":"National\u00a0Key\u00a0R&D\u00a0Program\u00a0of\u00a0China","doi-asserted-by":"crossref","award":["2023YFC2411603 (ZXL)"],"award-info":[{"award-number":["2023YFC2411603 (ZXL)"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Sanbo Brain Hospital Management Group","award":["SBJT-KY-2020-002 (ZXL)"],"award-info":[{"award-number":["SBJT-KY-2020-002 (ZXL)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This review provide a comprehensive overview of the molecular biology and therapeutic advances regarding papillary craniopharyngiomas (PCP), with a particular focus on the pivotal role of the BRAF V600E mutation in its pathogenesis. Histopathologically, PCPs are characterized by stratified squamous epithelium and are frequently associated with the BRAF V600E mutation. This mutation activates the MAPK\/ERK signaling pathway, which drives tumor development and progression. The identification of this pathway has led to significant progress in targeted therapies, specifically with the use of BRAF and MEK inhibitors, which have demonstrated remarkable efficacy in clinical trials. These inhibitors can effectively reduce tumor size and improve clinical outcomes for patients. However, despite these advancements, there are challenges such as the potential for resistance to these therapies and the management of long-term side effects. Consequently, a multidisciplinary approach that combines surgical resection, radiation therapy, and targeted therapy is often recommended to enhance treatment efficacy although minimizing adverse effects. In addition to adult cases, this review also addresses rare instances of pediatric PCP. Although these cases are infrequent, their molecular characteristics closely resemble those of adult PCP, suggesting that similar therapeutic approaches might be applicable. Looking ahead, future research should focus on optimizing treatment regimens, understanding the interactions within the tumor's immune microenvironment, and identifying novel therapeutic targets. These efforts are crucial for enhancing precision medicine strategies for PCP patients, ultimately improving their quality of life and long-term prognosis. Overall, continued exploration in this field holds promise for more effective and tailored treatment options.<\/jats:p>","DOI":"10.1007\/s12032-025-02920-0","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T17:47:10Z","timestamp":1753206430000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeted therapy of papillary craniopharyngioma"],"prefix":"10.1007","volume":"42","author":[{"given":"Ning","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"2920_CR1","doi-asserted-by":"publisher","first-page":"547","DOI":"10.3171\/jns.1998.89.4.0547","volume":"89","author":"GR Bunin","year":"1998","unstructured":"Bunin GR, Surawicz TS, Witman PA, Preston-Martin S, Davis F, Bruner JM. The descriptive epidemiology of craniopharyngioma. J Neurosurg. 1998;89:547\u201351.","journal-title":"J Neurosurg"},{"key":"2920_CR2","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1093\/neuonc\/nov044","volume":"17","author":"AS Sterkenburg","year":"2015","unstructured":"Sterkenburg AS, Hoffmann A, Gebhardt U, Warmuth-Metz M, Daubenb\u00fcchel AMM, M\u00fcller HL. Survival, hypothalamic obesity, and neuropsychological\/psychosocial status after childhood-onset craniopharyngioma: newly reported long-term outcomes. Neuro Oncol. 2015;17:1029\u201338.","journal-title":"Neuro Oncol"},{"key":"2920_CR3","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/00006123-200002000-00007","volume":"46","author":"JM Duff","year":"2000","unstructured":"Duff JM, Meyer FB, Ilstrup DM, Laws ER, Schleck CD, Scheithauer BW. Long-term outcomes for surgically resected craniopharyngiomas. Neurosurgery. 2000;46:291\u2013305.","journal-title":"Neurosurgery"},{"key":"2920_CR4","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1530\/eje.1.02114","volume":"154","author":"OM Dekkers","year":"2006","unstructured":"Dekkers OM, Biermasz NR, Smit JWA, Groot LE, Roelfsema F, Romijn JA, et al. Quality of life in treated adult craniopharyngioma patients. Eur J Endocrinol. 2006;154:483\u20139.","journal-title":"Eur J Endocrinol"},{"key":"2920_CR5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/jnen\/61.3.215","volume":"61","author":"P Kleihues","year":"2002","unstructured":"Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002;61:215\u201325 (discussion 226\u20139).","journal-title":"J Neuropathol Exp Neurol"},{"key":"2920_CR6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","volume":"114","author":"DN Louis","year":"2007","unstructured":"Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97\u2013109.","journal-title":"Acta Neuropathol"},{"key":"2920_CR7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1750-3639.1993.tb00752.x","volume":"3","author":"P Kleihues","year":"1993","unstructured":"Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol. 1993;3:255\u201368.","journal-title":"Brain Pathol"},{"key":"2920_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/BF00342596","volume":"19","author":"KJ Z\u00fclch","year":"1980","unstructured":"Z\u00fclch KJ. Principles of the new World Health Organization (WHO) classification of brain tumors. Neuroradiology. 1980;19:59\u201366.","journal-title":"Neuroradiology"},{"key":"2920_CR9","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803\u201320.","journal-title":"Acta Neuropathol"},{"key":"2920_CR10","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231\u201351.","journal-title":"Neuro Oncol"},{"issue":"5","key":"2920_CR11","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/neuonc\/noaf030","volume":"27","author":"W An","year":"2025","unstructured":"An W, Li S, An Y, Lin Z. Molecular subtypes of adamantinomatous craniopharyngiomas. Neuro Oncol. 2025;27(5):1180\u201392.","journal-title":"Neuro Oncol"},{"key":"2920_CR12","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ng.2868","volume":"46","author":"PK Brastianos","year":"2014","unstructured":"Brastianos PK, Taylor-Weiner A, Manley PE, Jones RT, Dias-Santagata D, Thorner AR, et al. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet. 2014;46:161\u20135.","journal-title":"Nat Genet"},{"key":"2920_CR13","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1016\/j.wneu.2022.05.115","volume":"165","author":"C Zhao","year":"2022","unstructured":"Zhao C, Zhou Z, Zhang Y, Qi X, Wang X, Lin D, et al. Diagnosis and management of pediatric papillary craniopharyngiomas. World Neurosurg. 2022;165:e148\u201358.","journal-title":"World Neurosurg"},{"key":"2920_CR14","first-page":"205846012110306","volume":"10","author":"K Takagi","year":"2021","unstructured":"Takagi K, Kikuchi K, Hiwatashi A, Togao O, Sangatsuda Y, Kuga D, et al. Papillary craniopharyngioma coexisting with an intratumoral abscess in a pediatric patient: a case report and review of the literature. Acta Radiol Open. 2021;10:205846012110306.","journal-title":"Acta Radiol Open"},{"key":"2920_CR15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40478-016-0287-6","volume":"4","author":"A H\u00f6lsken","year":"2016","unstructured":"H\u00f6lsken A, Sill M, Merkle J, Schweizer L, Buchfelder M, Flitsch J, et al. Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles. Acta Neuropathol Commun. 2016;4:20.","journal-title":"Acta Neuropathol Commun"},{"key":"2920_CR16","first-page":"126","volume":"76","author":"T Goschzik","year":"2017","unstructured":"Goschzik T, Gessi M, Dreschmann V, Gebhardt U, Wang L, Yamaguchi S, et al. Genomic alterations of adamantinomatous and papillary craniopharyngioma. J Neuropathol Exp Neurol. 2017;76:126\u201334.","journal-title":"J Neuropathol Exp Neurol"},{"key":"2920_CR17","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/CM9.0000000000002774","volume":"137","author":"X Wang","year":"2023","unstructured":"Wang X, Zhao C, Lin J, Liu H, Zeng Q, Chen H, et al. Multi-omics analysis of adamantinomatous craniopharyngiomas reveals distinct molecular subgroups with prognostic and treatment response significance. Chin Med J (Engl). 2023;137:859\u201370.","journal-title":"Chin Med J (Engl)"},{"key":"2920_CR18","doi-asserted-by":"publisher","first-page":"102205","DOI":"10.1016\/j.cbpa.2022.102205","volume":"71","author":"A Gunderwala","year":"2022","unstructured":"Gunderwala A, Cope N, Wang Z. Mechanism and inhibition of BRAF kinase. Curr Opin Chem Biol. 2022;71:102205.","journal-title":"Curr Opin Chem Biol"},{"key":"2920_CR19","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00018-022-04296-0","volume":"79","author":"RC Maloney","year":"2022","unstructured":"Maloney RC, Zhang M, Liu Y, Jang H, Nussinov R. The mechanism of activation of MEK1 by B-Raf and KSR1. Cell Mol Life Sci. 2022;79:281.","journal-title":"Cell Mol Life Sci"},{"key":"2920_CR20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1056\/NEJMe2305288","volume":"389","author":"JO Blakeley","year":"2023","unstructured":"Blakeley JO, Shannon K. Precision oncology for papillary craniopharyngioma. N Engl J Med. 2023;389:179\u201381.","journal-title":"N Engl J Med"},{"key":"2920_CR21","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1158\/1535-7163.MCT-10-0799","volume":"10","author":"ER Cantwell-Dorris","year":"2011","unstructured":"Cantwell-Dorris ER, O\u2019Leary JJ, Sheils OM. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther. 2011;10:385\u201394.","journal-title":"Mol Cancer Ther"},{"key":"2920_CR22","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","volume":"8","author":"ME Bahar","year":"2023","unstructured":"Bahar ME, Kim HJ, Kim DR. Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct Target Ther. 2023;8:455.","journal-title":"Signal Transduct Target Ther"},{"key":"2920_CR23","first-page":"2141","volume":"144","author":"S Haston","year":"2017","unstructured":"Haston S, Pozzi S, Carreno G, Manshaei S, Panousopoulos L, Gonzalez-Meljem JM, et al. MAPK pathway control of stem cell proliferation and differentiation in the embryonic pituitary provides insights into the pathogenesis of papillary craniopharyngioma. Development. 2017;144:2141\u201352.","journal-title":"Development"},{"key":"2920_CR24","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1038\/s41467-021-22640-z","volume":"12","author":"W Mu","year":"2021","unstructured":"Mu W, Li S, Xu J, Guo X, Wu H, Chen Z, et al. Hypothalamic Rax+ tanycytes contribute to tissue repair and tumorigenesis upon oncogene activation in mice. Nat Commun. 2021;12:2288.","journal-title":"Nat Commun"},{"key":"2920_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrendo.2017.124","volume":"14","author":"J Clasadonte","year":"2017","unstructured":"Clasadonte J, Prevot V. The special relationship: glia-neuron interactions in the neuroendocrine hypothalamus. Nat Rev Endocrinol. 2017;14:25\u201344.","journal-title":"Nat Rev Endocrinol"},{"key":"2920_CR26","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/B978-0-12-820107-7.00015-X","volume":"180","author":"H-W Korf","year":"2021","unstructured":"Korf H-W, M\u00f8ller M. Arcuate nucleus, median eminence, and hypophysial pars tuberalis. Handb Clin Neurol. 2021;180:227\u201351.","journal-title":"Handb Clin Neurol"},{"key":"2920_CR27","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/B978-0-12-820107-7.00016-1","volume":"180","author":"V Prevot","year":"2021","unstructured":"Prevot V, Nogueiras R, Schwaninger M. Tanycytes in the infundibular nucleus and median eminence and their role in the blood\u2013brain barrier. Handb Clin Neurol. 2021;180:253\u201373.","journal-title":"Handb Clin Neurol"},{"key":"2920_CR28","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.peptides.2010.01.003","volume":"31","author":"EM Rodr\u00edguez","year":"2010","unstructured":"Rodr\u00edguez EM, Bl\u00e1zquez JL, Guerra M. The design of barriers in the hypothalamus allows the median eminence and the arcuate nucleus to enjoy private milieus: the former opens to the portal blood and the latter to the cerebrospinal fluid. Peptides. 2010;31:757\u201376.","journal-title":"Peptides"},{"key":"2920_CR29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1210\/endrev\/bnae028","volume":"46","author":"R Prieto","year":"2024","unstructured":"Prieto R, Juratli TA, Bander ED, Santagata S, Barrios L, Brastianos PK, et al. Papillary craniopharyngioma: an integrative and comprehensive review. Endocr Rev. 2024;46:151\u2013213.","journal-title":"Endocr Rev"},{"key":"2920_CR30","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1093\/neuonc\/noy035","volume":"20","author":"S Coy","year":"2018","unstructured":"Coy S, Rashid R, Lin J-R, Du Z, Donson AM, Hankinson TC, et al. Multiplexed immunofluorescence reveals potential PD-1\/PD-L1 pathway vulnerabilities in craniopharyngioma. Neuro Oncol. 2018;20:1101\u201312.","journal-title":"Neuro Oncol"},{"key":"2920_CR31","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.bbrc.2019.04.142","volume":"514","author":"C Chen","year":"2019","unstructured":"Chen C, Wang Y, Zhong K, Jiang C, Wang L, Yuan Z, et al. Frequent B7\u2013H3 overexpression in craniopharyngioma. Biochem Biophys Res Commun. 2019;514:379\u201385.","journal-title":"Biochem Biophys Res Commun"},{"key":"2920_CR32","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.3390\/biom12121744","volume":"12","author":"M Tang","year":"2022","unstructured":"Tang M, Chen C, Wang G, Wang Y, Zhang Z, Li H, et al. Evaluation of B7\u2013H3 targeted immunotherapy in a 3D organoid model of craniopharyngioma. Biomolecules. 2022;12:1744.","journal-title":"Biomolecules"},{"key":"2920_CR33","doi-asserted-by":"publisher","first-page":"995655","DOI":"10.3389\/fimmu.2022.995655","volume":"13","author":"Y Jia","year":"2022","unstructured":"Jia Y, Ma L, Cai K, Zhang B, Wu W, Xiao Y, et al. Immune infiltration in aggressive papillary craniopharyngioma: high infiltration but low action. Front Immunol. 2022;13:995655.","journal-title":"Front Immunol"},{"key":"2920_CR34","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1016\/j.wneu.2019.02.212","volume":"127","author":"D Lin","year":"2019","unstructured":"Lin D, Wang Y, Zhou Z, Lin Z. Immune microenvironment of primary and recurrent craniopharyngiomas: a study of the differences and clinical significance. World Neurosurg. 2019;127:e212\u201320.","journal-title":"World Neurosurg"},{"key":"2920_CR35","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3171\/jns.1969.30.4.0377","volume":"30","author":"DD Matson","year":"1969","unstructured":"Matson DD, Crigler JF. Management of craniopharyngioma in childhood. J Neurosurg. 1969;30:377\u201390.","journal-title":"J Neurosurg"},{"key":"2920_CR36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3171\/jns.1992.76.1.0047","volume":"76","author":"HJ Hoffman","year":"1992","unstructured":"Hoffman HJ, Silva MD, Humphreys RP, Drake JM, Smith ML, Blaser SI. Aggressive surgical management of craniopharyngiomas in children. J Neurosurg. 1992;76:47\u201352.","journal-title":"J Neurosurg"},{"key":"2920_CR37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3171\/jns.1990.73.1.0003","volume":"73","author":"MG Ya\u015fargil","year":"1990","unstructured":"Ya\u015fargil MG, Curcic M, Kis M, Siegenthaler G, Teddy PJ, Roth P. Total removal of craniopharyngiomas. J Neurosurg. 1990;73:3\u201311.","journal-title":"J Neurosurg"},{"key":"2920_CR38","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1227\/00006123-199504000-00012","volume":"36","author":"G Maira","year":"1995","unstructured":"Maira G, Anile C, Rossi GF, Colosimo C. Surgical treatment of craniopharyngiomas. Neurosurgery. 1995;36:715\u201324.","journal-title":"Neurosurgery"},{"key":"2920_CR39","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1093\/neurosurgery\/23.CN_suppl_1.52","volume":"23","author":"WH Sweet","year":"1976","unstructured":"Sweet WH. Radical surgical treatment of craniopharyngioma. Neurosurgery. 1976;23:52\u201379.","journal-title":"Neurosurgery"},{"key":"2920_CR40","doi-asserted-by":"crossref","unstructured":"Piloni M, Gagliardi F, Bailo M, Losa M, Boari N, Spina A, et al. Craniopharyngioma in pediatrics and adults. In: Sex Gend Factor Affect Metab Homeost Diabetes Obes. Cham: Springer International Publishing; 2023. p. 299\u2013329.","DOI":"10.1007\/978-3-031-23705-8_11"},{"key":"2920_CR41","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3109\/02699052.2015.1104552","volume":"30","author":"D Preece","year":"2016","unstructured":"Preece D, Allan A, Becerra R. A case study of the neuropsychological outcomes following microsurgery, conventional radiotherapy and stereotactic radiotherapy for an adult\u2019s recurrent craniopharyngioma. Brain Inj. 2016;30:104\u201311.","journal-title":"Brain Inj"},{"key":"2920_CR42","first-page":"447","volume":"77","author":"T Kobayashi","year":"2015","unstructured":"Kobayashi T, Tsugawa T, Hatano M, Hashizume C, Mori Y, Shibamoto Y. Gamma knife radiosurgery of craniopharyngioma: results of 30 cases treated at Nagoya Radiosurgery Center. Nagoya J Med Sci. 2015;77:447.","journal-title":"Nagoya J Med Sci"},{"key":"2920_CR43","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.wneu.2015.06.022","volume":"84","author":"S Takano","year":"2015","unstructured":"Takano S, Akutsu H, Mizumoto M, Yamamoto T, Tsuboi K, Matsumura A. Neuroendoscopy followed by radiotherapy in cystic craniopharyngiomas\u2014a long-term follow-up. World Neurosurg. 2015;84:1305-1315.e2.","journal-title":"World Neurosurg"},{"key":"2920_CR44","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/00006123-199702000-00006","volume":"40","author":"J Voges","year":"1997","unstructured":"Voges J, Sturm V, Lehrke R, Treuer H, Gauss C, Berthold F. Cystic craniopharyngioma: long-term results after intracavitary irradiation with stereotactically applied colloidal \u03b2-emitting radioactive sources. Neurosurgery. 1997;40:263\u201370.","journal-title":"Neurosurgery"},{"key":"2920_CR45","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/neurosurgery\/46.1.213","volume":"46","author":"A Savas","year":"2000","unstructured":"Savas A, Erdem A, Tun K, Kanpolat Y. Fatal toxic effect of bleomycin on brain tissue after intracystic chemotherapy for a craniopharyngioma: case report. Neurosurgery. 2000;46:213\u20137.","journal-title":"Neurosurgery"},{"key":"2920_CR46","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1007\/s00381-001-0524-5","volume":"17","author":"C Mottolese","year":"2001","unstructured":"Mottolese C, Stan H, Hermier M, Berlier P, Convert J, Frappaz D, et al. Intracystic chemotherapy with bleomycin in the treatment of craniopharyngiomas. Child\u2019s Nerv Syst. 2001;17:724\u201330.","journal-title":"Child\u2019s Nerv Syst"},{"key":"2920_CR47","doi-asserted-by":"publisher","first-page":"E12","DOI":"10.3171\/2010.1.FOCUS09310","volume":"28","author":"S Cavalheiro","year":"2010","unstructured":"Cavalheiro S, Di Rocco C, Valenzuela S, Dastoli PA, Tamburrini G, Massimi L, et al. Craniopharyngiomas: intratumoral chemotherapy with interferon-alpha: a multicenter preliminary study with 60 cases. Neurosurg Focus. 2010;28:E12.","journal-title":"Neurosurg Focus"},{"key":"2920_CR48","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M, Atkinson V, Mandal\u00e0 M, Chiarion-Sileni V, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377:1813\u201323.","journal-title":"N Engl J Med"},{"key":"2920_CR49","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMoa1502309","volume":"373","author":"DM Hyman","year":"2015","unstructured":"Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay J-Y, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373:726\u201336.","journal-title":"N Engl J Med"},{"key":"2920_CR50","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1002011","volume":"363","author":"KT Flaherty","year":"2010","unstructured":"Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809\u201319.","journal-title":"N Engl J Med"},{"key":"2920_CR51","doi-asserted-by":"publisher","first-page":"djv310","DOI":"10.1093\/jnci\/djv310","volume":"108","author":"PK Brastianos","year":"2015","unstructured":"Brastianos PK, Shankar GM, Gill CM, Taylor-Weiner A, Nayyar N, Panka DJ, et al. Dramatic response of BRAF V600E mutant papillary craniopharyngioma to targeted therapy. JNCIJ. 2015;108:djv310.","journal-title":"JNCIJ"},{"key":"2920_CR52","doi-asserted-by":"publisher","first-page":"R139","DOI":"10.1530\/EJE-15-0957","volume":"174","author":"PK Brastianos","year":"2016","unstructured":"Brastianos PK, Santagata S. ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma. Eur J Endocrinol. 2016;174:R139\u201344.","journal-title":"Eur J Endocrinol"},{"key":"2920_CR53","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s11102-015-0663-4","volume":"19","author":"SJB Aylwin","year":"2015","unstructured":"Aylwin SJB, Bodi I, Beaney R. Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor. Pituitary. 2015;19:544\u20136.","journal-title":"Pituitary"},{"key":"2920_CR54","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2217\/cns-2016-0034","volume":"6","author":"A Roque","year":"2017","unstructured":"Roque A, Odia Y. BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors. CNS Oncol. 2017;6:95\u20139.","journal-title":"CNS Oncol"},{"key":"2920_CR55","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1007\/s00701-017-3311-0","volume":"159","author":"E Rostami","year":"2017","unstructured":"Rostami E, Witt Nystr\u00f6m P, Libard S, Wikstr\u00f6m J, Casar-Borota O, Gudjonsson O. Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy. Acta Neurochir. 2017;159:2217\u201321.","journal-title":"Acta Neurochir"},{"key":"2920_CR56","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3171\/2017.11.JNS172373","volume":"130","author":"BT Himes","year":"2019","unstructured":"Himes BT, Ruff MW, Van Gompel JJ, Park SS, Galanis E, Kaufmann TJ, et al. Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with dabrafenib: case report. JNS. 2019;130:1299\u2013303.","journal-title":"JNS"},{"key":"2920_CR57","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1002\/cncr.32197","volume":"125","author":"TA Juratli","year":"2019","unstructured":"Juratli TA, Jones PS, Wang N, Subramanian M, Aylwin SJB, Odia Y, et al. Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations. Cancer. 2019;125:2910\u20134.","journal-title":"Cancer"},{"key":"2920_CR58","doi-asserted-by":"publisher","first-page":"6038","DOI":"10.18632\/oncotarget.27203","volume":"10","author":"M Rao","year":"2019","unstructured":"Rao M, Bhattacharjee M, Shepard S, Hsu S. Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report. Oncotarget. 2019;10:6038\u201342.","journal-title":"Oncotarget"},{"key":"2920_CR59","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.6004\/jnccn.2020.7624","volume":"18","author":"K Khaddour","year":"2020","unstructured":"Khaddour K, Chicoine MR, Huang J, Dahiya S, Ansstas G. Successful use of BRAF\/MEK inhibitors as a neoadjuvant approach in the definitive treatment of papillary craniopharyngioma. J Natl Compr Canc Netw. 2020;18:1590\u20135.","journal-title":"J Natl Compr Canc Netw"},{"key":"2920_CR60","doi-asserted-by":"publisher","first-page":"bvab043","DOI":"10.1210\/jendso\/bvab043","volume":"5","author":"CL Chik","year":"2021","unstructured":"Chik CL, van Landeghem FKH, Easaw JC, Mehta V. Aggressive childhood-onset papillary craniopharyngioma managed with vemurafenib, a BRAF inhibitor. J Endocr Soc. 2021;5:bvab043.","journal-title":"J Endocr Soc"},{"key":"2920_CR61","doi-asserted-by":"publisher","first-page":"882381","DOI":"10.3389\/fendo.2022.882381","volume":"13","author":"F Calvanese","year":"2022","unstructured":"Calvanese F, Jacquesson T, Manet R, Vasiljevic A, Lasolle H, Ducray F, et al. Neoadjuvant B-RAF and MEK inhibitor targeted therapy for adult papillary craniopharyngiomas: a new treatment paradigm. Front Endocrinol. 2022;13:882381.","journal-title":"Front Endocrinol"},{"key":"2920_CR62","first-page":"e40190","volume":"15","author":"SN Shah","year":"2023","unstructured":"Shah SN, Kaki PC, Shah SS, Shah SA. Concurrent radiation and targeted therapy for papillary craniopharyngioma: a case report. Cureus. 2023;15:e40190.","journal-title":"Cureus"},{"key":"2920_CR63","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s11102-023-01339-y","volume":"26","author":"AL Lin","year":"2023","unstructured":"Lin AL, Tabar V, Young RJ, Geer EB. Dabrafenib as a diagnostic and therapeutic strategy for the non-surgical management of papillary craniopharyngioma. Pituitary. 2023;26:482\u20137.","journal-title":"Pituitary"},{"key":"2920_CR64","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa2213329","volume":"389","author":"PK Brastianos","year":"2023","unstructured":"Brastianos PK, Twohy E, Geyer S, Gerstner ER, Kaufmann TJ, Tabrizi S, et al. BRAF\u2013MEK inhibition in newly diagnosed papillary craniopharyngiomas. N Engl J Med. 2023;389:118\u201326.","journal-title":"N Engl J Med"},{"key":"2920_CR65","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1007\/s40618-024-02382-7","volume":"11","author":"M Losa","year":"2024","unstructured":"Losa M, Mazza E, Pedone E, Nocera G, Liscia N, Reni M, et al. Targeted therapy in BRAF mutated aggressive papillary craniopharyngioma: a case report and overview of the literature. J Endocrinol Investig. 2024;11:2835\u201342.","journal-title":"J Endocrinol Investig"},{"key":"2920_CR66","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/ejendo\/lvae091","volume":"191","author":"D De Alcubierre","year":"2024","unstructured":"De Alcubierre D, Gkasdaris G, Mordrel M, Joncour A, Briet C, Almairac F, et al. BRAF and MEK inhibitor targeted therapy in papillary craniopharyngiomas: a cohort study. Eur J Endocrinol. 2024;191:251\u201361.","journal-title":"Eur J Endocrinol"},{"key":"2920_CR67","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41571-023-00807-5","volume":"20","author":"P Sidaway","year":"2023","unstructured":"Sidaway P. BRAF plus MEK inhibition effective in papillary craniopharyngioma. Nat Rev Clin Oncol. 2023;20:661\u2013661.","journal-title":"Nat Rev Clin Oncol"},{"key":"2920_CR68","first-page":"2","volume":"2","author":"C Kassab","year":"2019","unstructured":"Kassab C, Zamler D, Kamiya-Matsuoka C, Gatalica Z, Xiu J, Spetzler D, et al. Genetic and immune profiling for potential therapeutic targets in adult human craniopharyngioma. Clin Oncol Res. 2019;2:2\u20138.","journal-title":"Clin Oncol Res"},{"key":"2920_CR69","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000048357","volume":"36","author":"Y-Q Zhang","year":"2002","unstructured":"Zhang Y-Q, Wang C-C, Ma Z-Y. Pediatric craniopharyngiomas: clinicomorphological study of 189 cases. Pediatr Neurosurg. 2002;36:80\u20134.","journal-title":"Pediatr Neurosurg"},{"key":"2920_CR70","doi-asserted-by":"publisher","first-page":"e763","DOI":"10.1097\/SCS.0000000000003176","volume":"27","author":"J Cheng","year":"2016","unstructured":"Cheng J, Shao Q, Pan Z, You J. Analysis and long-term follow-up of the surgical treatment of children with craniopharyngioma. J Craniofac Surg. 2016;27:e763\u20136.","journal-title":"J Craniofac Surg"},{"key":"2920_CR71","doi-asserted-by":"publisher","first-page":"570","DOI":"10.4103\/neuroindia.NI_552_16","volume":"65","author":"N Din","year":"2017","unstructured":"Din N, Tariq M, Ahmad Z, Memon W. Papillary craniopharyngioma: a clinicopathologic study of a rare entity from a major tertiary care center in Pakistan. Neurol India. 2017;65:570.","journal-title":"Neurol India"},{"key":"2920_CR72","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fgene.2018.00049","volume":"9","author":"S-M Schlaffer","year":"2018","unstructured":"Schlaffer S-M, Buchfelder M, Stoehr R, Buslei R, H\u00f6lsken A. Rathke\u2019s cleft cyst as origin of a pediatric papillary craniopharyngioma. Front Genet. 2018;9:49.","journal-title":"Front Genet"},{"key":"2920_CR73","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00381-018-3925-4","volume":"35","author":"R Borrill","year":"2018","unstructured":"Borrill R, Cheesman E, Stivaros S, Kamaly-Asl ID, Gnanalingham K, Kilday J-P. Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature. Childs Nerv Syst. 2018;35:169\u201373.","journal-title":"Childs Nerv Syst"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02920-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02920-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02920-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T18:49:29Z","timestamp":1757270969000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02920-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":73,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["2920"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02920-0","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"367"}}